Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good ...shake the tree

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on Jul 14, 2021 3:32pm

164 Views

Post# 33543677

RE:Good ...shake the tree

Tbh i'm realizing the only fools are me, you and anyone who is holding. The once who are selling probably will get in at lower sp and the once who are buying have a cheaper average than us.

When sp falls from heaven to hell our ceo who is the one to blame. Lots of fake promises, always delays and not to mention financing ph3 just after nuance deal. He basically did that on our backs

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario